Add-on histamine receptor-3 antagonist for allergic rhinitis: a double blind randomized crossover trial using the environmental exposure unit

Table 4 Post-Hoc analysis of mean symptom scores (2H – 6H)

Treatment	N	Parameter	Mean ± SE	95% Confidence interval	Adj. p-value to placebo
Placebo	14	Congestion	2.00 ± 0.18	(1.64, 2.36)	N/A
Placebo	14	TNSS	5.51 ± 0.50	(4.53, 6.49)	N/A
PF-03654764	28	Congestion	1.90 ± 0.15	(1.59, 2.20)	0.939
PF-03654764	28	TNSS	4.84 ± 0.42	(4.00, 5.67)	0.186
PF-03654764 + fexofenadine	86	Congestion	1.58 ± 0.10	(1.39, 1.78)	0.138
PF-03654764 + fexofenadine	86	TNSS	3.63 ± 0.27	(3.10, 4.16)	0.001
Pseudoephedrine + fexofenadine	97	Congestion	1.50 ± 0.09	(1.31, 1.68)	0.034
Pseudoephedrine + fexofenadine	97	TNSS	3.70 ± 0.25	(3.20, 4.20)	0.003

Mean symptom scores for congestion and Total Nasal Symptom Score (TNSS) were calculated by taking the least squares mean between 2H and 6H post-treatment. Standard error (SE) of the mean and 95% confidence intervals were also calculated for each treatment. N = number of participant study periods on each treatment. Groups were compared using a mixed model ANCOVA and the Tukey-Kramer adjustment was used to control for multiple comparison.

ISSN: 1710-1492